AI-generated summary
The authors report a randomized, placebo-controlled trial of low-level laser therapy in 43 patients with hypothyroidism caused by chronic autoimmune thyroiditis. Compared with placebo, the laser group needed a lower levothyroxine dose to control hypothyroidism after withdrawal, with lower thyroid peroxidase antibodies and greater thyroid echogenicity. No difference in thyroglobulin antibodies was observed.
- Participants
- 43
- Who or what was studied
- Patients with chronic autoimmune thyroiditis-induced hypothyroidism who had a history of levothyroxine therapy
- Wavelengths
- 830 nm
- Limits stated in the abstract
- The abstract does not describe how many patients were in each group beyond 23 and 20, and it reports a single trial with a 9-month follow-up, so long-term effects and generalizability are not established.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 830 nm
- Power
- 50 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Placebo-controlled, Laser, Dose, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.